1-100 – Opening Ceremony – Francis Munier

1-101 – Franceschetti Lecture – Graeme Black

“The Guide is definitive. Reality is frequently inaccurate.” – Douglas Adams, The Hitchhiker’s Guide to the Galaxy

1-103 – Caroline Atef Tawfik

Clinical and Genetic Characterization of IMPG2-Associated Retinopathy in an Egyptian Cohort

1-104 – Goura Chattannavar

Homozygous R383H variant in IDUA gene causing Pericentric Retinitis Pigmentosa in attenuated Mucopolysaccharidosis Type I

1-105 – Piet Noë

Retinoblastoma treatment at a charitable eye hospital in Rwanda

1-106 – Mette Bertelsen

A nationwide overview of the clinical and genetic landscape of inherited ocular disorders in Denmark

1-108 – Arif O Khan

A homozygous NRL variant (c.339C>G; p.Try113*) underlies enhanced-S-cone syndrome in the United Arab Emirates and is associated with an electronegative electroretinogram

1-109 – Beau J Fenner

How Does the Diagnosis of Inherited Retinal Disease Influence Reproductive Decision-Making in Singapore?

1-110 – Dorothy Wang

Clinical and Genetic Characterization of Inherited Retinal Diseases in a Diverse North American Cohort of Over 1,800 Cases

1-111 – Xènia Ferrer-Cortès

New insights on the genetic basis underlying hereditary high myopia in a cohort of more than 100 Spanish families

1-114 – Ulrika Kjellström

A case series: The description of a family with autosomal dominant KCNJ13 associated retinal dystrophy and a novel phenotype

1-115 – Ragnhild Wivestad Jansson

A novel deletion in 3’UTR of the retina-specific isoform of RPGR leads to reduced expression of RPGR in a family with X-linked retinitis pigmentosa.

1-116 – Erlend C S Landsend

Substantial difference in ocular phenotype and follow-up of two patients with KIF11 -mutation

1-117 – Dong Hyun Jo

Clinical Characterization of NMNAT1 -Associated Leber Congenital Amaurosis in a Korean Cohort

1-118 – Laura Mauring

Cone-Rod Dystrophy due to a Homozygous KIZ Variant

1-119 – Miriam Ehrenberg

Patchy perifoveal chorioretinal atrophy related to a novel gene: C19ORF44

1-120 – Evangelia Panagiotou

A rare case of RAB28 -related retinal disease due to complete uniparental isodisomy of chromosome 4

1-121 – Suma P Shankar

Micro RNA 204 (MIR204 ) as a novel cause of persistent pupillary membrane, high myopia, coloboma and lens opacity: a case study

1-124 – Michelle Lingao

First case report of Wolfram Syndrome type 1 in the Philippines: Diagnostic challenges and discovery of a novel Exon 3 WFS1 heterozygous nonsense mutation

1-125 – Alena Egense

NBAS -related short stature, optic nerve atrophy, and Pelger-Huet anomaly (SOPH) presenting as early- onset optic atrophy

1-126 – Karthikeyan Arcot Sadagopan

Microspherophakia, inguinal hernia, tortuous retinal vessels & facial dysmorphism as the presenting features in Six Indian Asian Children with Traboulsi syndrome and report of a novel pathogenic variant in the ASPH gene.

1-127 – Annamari Immonen

Phenotypically Mild Congenital Stromal Corneal Dystrophy in a Finnish Family Caused by a Novel Missense Variant c.1036T>C in the Decorin Gene

1-128 – Ana Ćurić

Giant Cyst of Dermis-Fat Graft Following Retinoblastoma Treatment Complicated with MRSA

 1-129 – Khitam Fakhir

An unexpected response of orbital retinoblastoma to inconsistent systemic chemotherapy alone. A case report

1-130 – Hiroyoshi Hattori

Three Case Reports of Retinoblastoma with Optic Nerve and CNS Invasion Treated with Multimodal Therapy Including Intrathecal and High-Dose Chemotherapy

1-131 – Małgorzata Danowska

Presumed bilateral ciliary body medulloepithelioma in a child with DICER1 syndrome and pleuropulmonary blastoma

2-103 – Liesbeth Gardoen

Guidelines on imaging of retinoblastoma : a 2025 update on behalf of the European Retinoblastoma Imaging Collaboration and the European Retinoblastoma Group

2-104 – Carme Julià

Leukocheck : a mobile app for the early detection of retinoblastoma

2-105 – Helen Dimaras

Uncertain heritable risk in retinoblastoma: Classification of genetic testing results for precision risk stratification

2-106 – Ashwin Mallipatna

Construction and validation of 3D-printed eyeball models in red reflex training of medical students

2-107 – Doris Hadjistilianou

Bilateral retinoblastoma and inner ear common cavity malformation : A novel association?

2-108 – Rebecca Clark

Novel, deep intronic RB1 variant exhibiting incomplete penetrance and a parent-of-origin effect

2-110 – Hannah L Scanga

Quantifying the Clinical Utility of Genetic Testing for Inherited Retinal Dystrophies to Inform Genetic Counseling

2-111 – Sandra Staffieri

There’s more to Leber Hereditary Optic Neuropathy than vision impairment: listening to everyone’s voice 

2-112 – David A Mackey

Detection of low-penetrance Leber Hereditary Optic Neuropathy (LHON) mtDNA variants in the general population

2-113 – Faeeqah Almhmoudi

Posterior Microphthalmia related to PRSS56 Variants in a Saudi Cohort: A Longitudinal Study of Visual Function

2-114 – Petra Ketteler

Genetic predisposition to melanoma of the choroid and ciliary body

2-115 – Mohamed H Abdel-Rahman

Genetic Predisposition to uveal melanoma

2-119 – Jasmina Cehajic-Kapetanovic

Special lecture: Gene therapy delivery

2-120 – Brittni Scruggs

Retinal Gene Therapy Using Epiretinal AAV-Containing Fibrin Hydrogel Implants

2-121 – Leonardo Colombo

Characterizing PRPF31-related Retinal Dystrophy: Clinical Insights from Baseline Data in a Natural History Study

2-122 – Kiyoko Gocho

Progression Assessment with OCT and Adaptive Optics: A Subset Analysis of the KEYS study

2-123 – Kirk Stephenson

Quantitative Choroidal Analysis in Molecularly Characterized Retinitis Pigmentosa

2-124 – Peter Francis

Efficacy Testing Facility for Low Vision Patients, the Vision Research and Assessment Institute “VRAI”

2-125 – Veronika Vaclavik

RP2 -Associated Rod Cone Dystrophy in Females Carriers: A Spectrum of Severity and follow up of 10 years

2-126 – Brooke Koritala

Eye-Related Quality of Life in Children with Inherited Retinal Diseases Using PedEyeQ

2-127 – Said El Shamieh

Copy-number variation significantly contributes to the pathogenicity of inherited retinal diseases in Lebanon

2-202 – Carlos E Mendoza-Santiesteban

Introduction to electrophysiology techniques (localized response; mfERG, Pattern ERG, pattern VEP

2-203 – Arlene Drack

Introductory cases pediatrics

2-204 – Juliana Maria Ferraz Sallum

Introductory cases adults

2-207 – Bart Leroy

Challenging case 1

2-208 – Carlos E Mendoza-Santiesteban

Challenging case 2

2-209 – Alina V Dumitrescu

Challenging case 3

2-211 – Sam Gurney

High dose intravitreal topotecan; a new therapy for retinal disease

2-212 – Francis Munier

High dose intravitreal Topotecan monotherapy for aqueous seeding, subretinal seeding and retinal relapse

2-213 – Joe Abbott

Intra-arterial chemotherapy: comparing techniques, does safety come at the cost of efficacy?

2-214 – Ida Russo

Early results of the national AIEOP RTB018 protocol

2-215 – Christina Stathopoulos

Risk factors for rhegmatogenous retinal detachment after intraarterial chemotherapy in endophytic retinoblastoma

2-217 – Ida Russo

Long-Term (>5-Year) remission and survival after immunotherapy with anti-GD2 monoclonal antibody dinutuximab Beta following autologous hematopoietic stem cell transplantation in a child with metastatic retinoblastoma

2-218 – Yan Honggai

Retinoblastoma patients died without high pathology Risk Factors

2-219 – Ashwin Reddy

EURBG survey on mortality at Retinoblastoma Centres in Europe 2012-2022 : Part 1 metastatic disease from retinoblastoma

2-220 – Livia Lumbroso-Le Rouic

EURBG survey on mortality at retinoblastoma centres in Europe 2012-2022 : Part 2 non metastatic deaths

2-221 – Emma Hughes

Supporting the psychosocial needs throughout the patient journey – The role of the play specialist.

2-222 – Annette Moll

Visual outcome of retinoblastoma patients in the Netherlands : a cohort study

2-223 – Anne Vestli

Retinoblastoma in Norway : Health-related quality of life and late effects

2-226 – Claudia Román-Montañana

Clinical variables associated with cell-free DNA yield obtained by anterior chamber tap in retinoblastoma

2-227 – Alexandre Matet

Aqueous humor cfDNA exploration in retinoblastoma can be superior to tumor DNA analysis: a case series

2-228 – Amy Gerrish

Genetic diagnosis of retinoblastoma via post chemotherapy anterior chamber tap

2-230 – Tatsiana Ryl

Collaborative study to identify Biomarkers to adjust treatment intensity for children with Retinoblastoma (CoBioRB) – A pilot study for the multicentre clinical trial EURBG2

2-231 – Lisa Golmard

Prognostic value of molecular markers in unilateral retinoblastoma treated by first-line enucleation

2-232 – Luigi Mazzeo

Mapping Retinoblastoma Heterogeneity with Spatially Resolved Transcriptomics

2-233 – Sima Das

Circulating cell-free tumor DNA-Based Liquid Biopsy of Cerebrospinal Fluid (CSF) in retinoblastoma

2-234 – Sima Das

Spatial Transcriptomics to Identify Differentially Expressed Genes in high-risk factor-positive Retinoblastoma versus Non-Aggressive Disease

3-102 – Andrea L. Vincent

Innovations in corneal dystrophy treatments

3-103 – Dimitri Roels

Syndromic diseases with corneal manifestations

3-105 – Liv Drolsum

Current clinical management of corneal dystrophies

3-107 – Andy Drackley

Updates on the ClinGen Pediatric Cataract VCEP’s CYP27A1 Guidelines Development

3-108 – Lev Prasov

RIGI variants cause a treatable glaucoma in humans and mice

3-109 – Meghal Gagrani

Phenotypic and genotypic characterization of Posterior polymorphous corneal dystrophy in children : a 13 year clinical review

3-113 – Tomas S. Aleman

Recovery of Cone-Mediated Vision in Severe Ciliopathies after Gene Therapy: One Year Results of a Phase I/II Trial for LCA5-LCA

3-114 – Valentina Di Iorio

LUCE-1: a phase 1/2, dose escalation, safety and efficacy study of administration of AAVB-081 gene therapy in Usher Syndrome type 1B (USH1B)

3-115 – Alina V Dumitrescu

Intravitreal Enzyme Replacement Therapy for Children with Neuronal Ceroid Lipofuscinosis Type 2, The University of Iowa experience

3-116 – Josephine Prener Holtan

A Phase 1B Multiple Ascending Dose Study of VP-001; a peptide conjugate of oligonucleotide designed to treat PRPF31 -related Retinitis Pigmentosa

3-117 – Mark Pennesi

Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN Trial, preliminary month 9+ results

3-118 – Bart Leroy

RNA-based therapy in Leber congenital amaurosis type 10 (LCA10): key lessons learned from the randomized double-masked, sham-controlled Phase 3 study of sepofarsen

3-121 – Andrea L Vincent

Genetic Drift and Founder Effects in CYP4V2 and PRPH2 -associated Inherited Retinal Disease Among Pasifika in Oceania

3-122 – Lotta Gränse

A case series: Multifocal Electroretinography (mfERG) for evaluation of macular function in children under four

3-123 – Alessio Amato

Negative Electroretinograms Beyond Congenital Stationary Night Blindness: Broadening the Differential Diagnosis of Post-Phototransduction Inherited Retinal Diseases

3-123-2 – Juliana Maria Ferraz Sallum

Microperimetry, a valuable tool for assessing changes in visual function following voretigene neparvovecrzyl gene therapy

3-125 – Arlene Drack

Subretinal gene therapy rescues cones >rods in a mouse model of Bardet-Biedl Syndrome Type 10

3-126 – Carlotta Librasi

A novel RNA therapeutic platform for Retinitis Pigmentosa 11

3-127 – Maya Helms

A murine model of microcephaly and chorioretinopathy reveals the importance of TUBGCP4 in vascular development

3-128 – Paula Gaudó

Deep characterization of mutant and CRISPR-corrected PDE6A and PDE6C retinal organoids derived from IRD patients

3-129 – Pascal Escher

To identify molecular mechanisms underlying NR2E3-linked retinal degenerations in murine knock-in models

3-130 – Rola Ba-Abbad

Clinical and Biochemical Characterization of Specific GUCY2D Alleles Associated With a Rare Form of Night Blindness

3-131 – Josephine Prener Holtan

AAVB-039: A dual AAV8.ABCA4 gene therapy for patients with Stargardt’s disease (STGD1)

3-202 – Manoj Parulekar

Clinical presentation and Diagnosis

3-203 – Christina Stathopoulous

Treatment modalities of intraocular retinoblastoma

3-204 – Amy Gerrish

The applications of cell-free DNA analysis.

3-205 – François Radvanyi

Molecular risk factors for retinoblastoma

3-207 – Magnar Bjørås

Patient-derived retinal organoids – Norwegian

3-208 – Daniel Chung

Gene-agnostic treatments – English

3-209 – Tomas Aleman

Clinical trial design and outcome measures – English

3-211 – Bart Leroy with Elias Traboulsi

Keynote Lecture: Current research status and remaining challenges for treatment of inherited retinal disorders – English